This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.
Deutsche Bank Reaffirms Their Hold Rating on Fresenius Medical Care AG & Co. KGaA (0H9X)
In a report released today, Falko Friedrichs from Deutsche Bank maintained a Hold rating on Fresenius Medical Care AG & Co. KGaA, with a price target of €42.00.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
According to TipRanks, Friedrichs is an analyst with an average return of -2.9% and a 40.32% success rate.
The word on The Street in general, suggests a Moderate Sell analyst consensus rating for Fresenius Medical Care AG & Co. KGaA with a €38.34 average price target.
The company has a one-year high of €54.02 and a one-year low of €35.67. Currently, Fresenius Medical Care AG & Co. KGaA has an average volume of 901.2K.
Read More on GB:0H9X:
Disclaimer & DisclosureReport an Issue
- Fresenius Medical price target lowered to EUR 42 from EUR 44 at Deutsche Bank
- Fresenius Medical price target lowered to EUR 34 from EUR 36 at Morgan Stanley
- Fresenius Medical reports Q4 EPS ex-items EUR1.44 vs. EUR0.91 last year
- Fresenius Medical sees 2026 revenue growth flat vs. EUR19.63B in 2025
- Sell Rating on Fresenius Medical Care Amid Unsustainable Earnings Quality and Structural Headwinds
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
